Daewoong Pharmaceutical company information, Employees & Contact Information

Daewoong’s CLOPAM patch enables injection-free, weekly semaglutide BioWorld MedTech

Ex-Celltrion veteran to head Daewoong’s new biosimilar division The Korea Herald

Daewoong’s semaglutide microneedle patch hits 80% absorption, challenges injection dominance koreabiomed.com

Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its botulinum toxin product NABOTA in Saudi Arabia PR Newswire

Daewoong Pharmaceutical Enters Global Biosimilar Market Businesskorea

Daewoong launches Nabota in Qatar, strengthens K-beauty in Middle East The Korea Herald

Daewoong’s microneedle patch marks semaglutide first in obesity European Pharmaceutical Review

Korea's Daewoong Bio banned from China drug procurement program after turning down inspection Fierce Pharma

Daewoong Pharmaceutical Announces 2023 Financial Results BioSpace

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease PR Newswire

Daewoong Pharmaceutical taps ex-Celltrion exec to lead global biosimilar push koreabiomed.com

Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion PR Newswire

Daewoong pulls BTX filing in China to align with regulatory changes koreabiomed.com

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio PR Newswire

Daewoong Pharmaceutical leads consortium to develop once-monthly obesity drug koreabiomed.com

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug PR Newswire

Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker PR Newswire

Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy PR Newswire

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet PR Newswire

Daewoong Pharmaceutical to unveil 3 anticancer pipelines at AACR 2025 koreabiomed.com

Daewoong and Celltrion Pharm to co-promote osteoporosis drug CT-P41 koreabiomed.com

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment BioSpace

Daewoong to work on digital twin bio manufacturing tech under state R&D project koreabiomed.com

Daewoong plots new $74.6M factory in South Korea to pump out Botox rival Fierce Pharma

Daewoong signs $53.6 mil. BTX export deal with Thai partner koreabiomed.com

Daewoong may end licensing deal with Vitalli Bio for autoimmune drug candidate koreabiomed.com

Daewoong gets patent of Nabota as migraine drug in US KED Global

Daewoong Pharma, Merck team up for AI tech for new drug KED Global

Daewoong wins permission for Nabota in Argentina KED Global

Daewoong Pharmaceutical steps onto global stage The Korea Herald

Daewoong's new co-CEO Park Seong-soo vows to achieve ₩1 tril. operating profit koreabiomed.com

Daewoong unveils new Indonesian stem cell facility with GMP certification The Korea Herald

Daewoong co-markets LG Chem’s combination drug for diabetes koreabiomed.com

Daewoong’s injection targets stubborn fat weight-loss drugs leave behind koreabiomed.com

Daewoong Pharma's GER drug gets product OK from Mexico KED Global

Daewoong's Nabota tops botulinum toxin exports The Korea Herald

Daewoong and Medytox to vie over submental fat reduction injections koreabiomed.com

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect KED Global

Daewoong’s Microneedle Patch Surpasses 80% Absorption Rate Businesskorea

Daewoong Pharmaceutical, SNU team to develop new flu drug 매일경제

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery Business Wire

Daewoong wins approval for GERD treatment Fexuclu in Chile KED Global

Daewoong Pharma wins permission from Singapore for Nabota KED Global

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments 美通社

Daewoong expands Nabota into 10 Middle Eastern countries - CHOSUNBIZ Chosun Biz

Daewoong to develop eye drops for diabetic retinopathy KED Global

Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion PR Newswire UK

Daewoong Business Breakthrough, Stem Cell Lab License Boosts Business Growth KONTAN